Validation of an Instrument to Measure Quality of Life in British Children With Inflammatory Bowel Disease

Abstract

IMPACT-III (UK) appears to be a useful tool to measure HRQoL in British children with IBD.

Medical staff tend to underestimate the quality of life in children and adolescents with inflammatory bowel disease

“…Abdominal pain, diarrhoea and bloody stools are the main symptoms of IBD, as this condition mainly involves the intestine . However, as it is a chronic disease that lasts for a lifetime, the disease may affect various aspects of the patient's life as well . Frequent hospital visits and school absences may affect school performance or relationships with peers.…”

IMPACT‐III is a valid and reliable questionnaire for assessing health‐related quality of life in Swedish children with inflammatory bowel disease

“…IMPACT was developed and first validated in Canada . Continued development and further studies suggest that IMPACT, currently in version III, is a reliable and valid instrument for measuring HRQoL among North American and British children . Although IMPACT‐III is the most widely accepted and validated instrument for this purpose, it is still under development .…”

“…Although IMPACT‐III is the most widely accepted and validated instrument for this purpose, it is still under development . The instrument has been translated into several languages and psychometrically tested with somewhat varying results . The aim of this study was to examine the reliability and validity and test the factor structure of a Swedish version of the tool – IMPACT‐III (SWE) – for measuring HRQoL in children and adolescents with IBD.…”

Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee

“…The paediatric IBD disease-specific health-related quality of life (HRQOL) instrument—the IMPACT questionnaire—was developed by a multidisciplinary research team41 42 using extensive patient item generation and reduction, and has been evaluated widely 43. Based on this and other evaluation, IMPACT II and then IMPACT III were developed44 and validated internationally 45. Of note, non-disease-specific variables, particularly behavioural dysfunction have been shown to have an important impact on HRQOL in paediatric IBD 46.…”